A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

This is a multicenter, open-label study enrolling a total of up to 23 patients.

Phase 1

Genentech, Inc.

Bevacizumab
Fluorouracil
Leucovorin
Oxaliplatin